266 related articles for article (PubMed ID: 17056024)
1. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
[TBL] [Abstract][Full Text] [Related]
3. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
[TBL] [Abstract][Full Text] [Related]
4. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
[TBL] [Abstract][Full Text] [Related]
5. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
6. Levels of soluble Fas/APO-1 in patients with Behçet's disease.
Hamzaoui K; Hamzaoui A; Zakraoui L; Chabbou A
Mediators Inflamm; 1998; 7(2):111-4. PubMed ID: 9836498
[TBL] [Abstract][Full Text] [Related]
7. Soluble HLA in saliva of patients with autoimmune rheumatic diseases.
Adamashvili I; Pressly T; Gebel H; Milford E; Wolf R; Mancini M; Sittg K; Ghali GE; Hall V; McDonald JC
Rheumatol Int; 2002 Jun; 22(2):71-6. PubMed ID: 12070679
[TBL] [Abstract][Full Text] [Related]
8. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
Zhao J; Zhao Y; He J; Jia R; Li Z
J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.
Goules A; Tzioufas AG; Manousakis MN; Kirou KA; Crow MK; Routsias JG
J Autoimmun; 2006 May; 26(3):165-71. PubMed ID: 16621447
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.
Orbach H; Zandman-Goddard G; Amital H; Barak V; Szekanecz Z; Szucs G; Danko K; Nagy E; Csepany T; Carvalho JF; Doria A; Shoenfeld Y
Ann N Y Acad Sci; 2007 Aug; 1109():385-400. PubMed ID: 17785327
[TBL] [Abstract][Full Text] [Related]
12. [Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases].
Harigai M; Hara M; Kamatani N; Kashiwazaki S
Ryumachi; 1999 Dec; 39(6):819-28. PubMed ID: 10695405
[TBL] [Abstract][Full Text] [Related]
13. Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases.
Mitsuo A; Morimoto S; Nakiri Y; Suzuki J; Kaneko H; Tokano Y; Tsuda H; Takasaki Y; Hashimoto H
Rheumatology (Oxford); 2006 Dec; 45(12):1477-84. PubMed ID: 16638798
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease.
Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H
Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856
[TBL] [Abstract][Full Text] [Related]
15. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.
Sahebari M; Hatef MR; Rezaieyazdi Z; Abbasi M; Abbasi B; Mahmoudi M
Arch Iran Med; 2010 Mar; 13(2):135-42. PubMed ID: 20187668
[TBL] [Abstract][Full Text] [Related]
16. Large macrophage colony-forming cells identical to high proliferative potential colony-forming cells in peripheral blood of patients with collagen vascular diseases: high occurrence among patients with systemic sclerosis and dermatomyositis.
Horie S; Minota S; Kano S
J Rheumatol; 2000 Oct; 27(10):2378-81. PubMed ID: 11036833
[TBL] [Abstract][Full Text] [Related]
17. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
18. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.
Ateş A; Kinikli G; Turgay M; Duman M
Clin Rheumatol; 2004 Oct; 23(5):421-5. PubMed ID: 15459814
[TBL] [Abstract][Full Text] [Related]
19. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel S; Rappl G; Tilgen W; Reinhold U
Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
[TBL] [Abstract][Full Text] [Related]
20. Serum angiopoietin-like protein 3 concentrations in rheumatic diseases.
Hayashi Y; Jinnin M; Makino T; Kajihara I; Makino K; Honda N; Nakayama W; Inoue K; Fukushima S; Ihn H
Eur J Dermatol; 2012; 22(4):500-4. PubMed ID: 22652544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
